28 September 2009 09:26 [Source: ICIS news]
LONDON (ICIS news)--Solvay has sold its pharmaceutical business to ?xml:namespace>
The enterprise value includes €4.5bn in cash, additional potential payments of up to €300m if certain milestones are reached and liabilities of €400m, the company added in a statement.
“This transaction is expected to be closed in the first quarter of 2010, pending the approval by relevant competition authorities,” the company added.
Solvay said that once the deal is closed the company planned to reinvest in “value-added activities and strategic projects in chemicals and plastics”.
Solvay’s CEO, Christian Jourquin, said: “We are building a new refocused group with the financial means to further accelerate sustainable growth on today’s strong foundations.”
The planned Solvay Investor Day, which was scheduled for 29 September, had been cancelled.
At 10:10 hours local time on the Euronext exchange in
($1 = €0.68)
To discuss issues facing the chemical industry visit ICIS connect
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.
|ICIS news FREE TRIAL|
|Get access to breaking chemical news as it happens.|
|ICIS Global Petrochemical Index (IPEX)|
|ICIS Global Petrochemical Index (IPEX). Download the free tabular data and a chart of the historical index|
Asian Chemical Connections